top of page
Web_tausta_mobiili.jpg
Webbisivun taustakuva 2.jpg
Web_tausta_mobiili.jpg
Webbisivun taustakuva 2.jpg
Ympyrä Lääkäri.png

Users

•  Primary Care Physicians

•  Family Doctors

•  Nurse Practitioners and Nurses

•  Pediatricians

•  ENT Specialists and Allergists

Webbisivun taustakuva 2.jpg

Who are we?

At Orcason Medical, we believe that modern, easy-to-use, and cost-effective diagnostic tools should be accessible to all healthcare providers, regardless of location. Our solution aims to simplify the diagnosis of sinusitis by providing fast and reliable results, enabling medical professionals to practice more precise medicine. We are committed to combating the rise of antibiotic-resistant bacteria, ensuring the long-term effectiveness of antibiotics for future generations.

•  Wireless POCUS ultrasound device for the scanning of sinuses

 

•  Detects the presence or absence of fluid in the sinus cavity

•  Fast, easy and reliable way to simplify sinusitis diagnosis

•  Applicable as standard of care for all suspected sinusitis cases

•  Reduces the amount of unnecessary antibiotic use.

Ympyrä kello.png
Ympyrä Käsi.png
Ympyrä Raha & Pills.png

Fast

•  No time consuming preparations

•  Immediate results on display

•  Short overall examination time

Safe

•  Poses no risks to patient or practitioner

•  Painless and non-invasive examination

•  No exposure to ionizing radiation

Effective

•  Significantly reduces misdiagnoses

•  Decreases unnecessary antibiotic use

•  Cost effective solution for everyone

Ympyrä Sairaala.png

Units

•  Hospitals

•  Primary Care Clinics

•  Specialty Clinics

•  Urgent Care Centers

•  Pharmacies

•  Home Healthcare Services

What are the benefits?

Million Users

2

LATAM

Testilaatikko 2.png

NAM

5

Million Users

Testilaatikko 3.png

Million Users

6

EMEA

APAC

9

Million Users

Million Users

GLOBAL

22

Million Users

APAC

9

Million Users

EMEA

6

Million Users

NAM

5

Million Users

LATAM

2

Market Potential

Investor Opportunities

•  Multibillion-dollar annual revenue opportunity as a global solution

•  Recurring revenue stream through probe covers and SaaS-solution

•  Largely unused technology with huge growth potential

•  No direct competitors in the current market

•  Strong possibility to crossover to B2C market with remote heathcare

What next? / Where you come in

We are collecting capital to ensure our launch and bring our solution avalable for everyone. This kind of text goes here.

Join Our Mission

Let’s make a difference and simplify sinusitis together. solution avalable for everyone. This kind of text goes here.

Download Full Presentation

•  Most sinusitis diagnoses are done on the basis of symptoms alone

•  Sinusitis is the leading single cause for antibiotic prescriptions

•  50% of antibiotic prescriptions for sinusitis are unnecessary

•  Unnecessary antibiotic use leads to the rise of  antimicrobial resistance

•  Over 30 million doctor visits every year in the US alone

Unnecessary antibiotic use leads to the rise of  antimicrobial resistance

Problem kuva 4.png

The Solution

Website Orsinus with Screen Clip.png

Wireless POCUS ultrasound device for the scanning of sinuses

Solution kuva Wifi.png

Detects the presence or absence of fluid in the sinus cavity

Solution kuva bakteeri.png

Fast, easy and reliable way to simplify sinusitis diagnosis

Solution kuva Kilpi.png

Fast, easy and reliable way to simplify sinusitis diagnosis

Solution Kuva Sydän.png

Reduces the amount of unnecessary antibiotic use.

Ympyrä Raha & Pills.png
Screenshot 2024-10-11 at 13.13_edited.jpg

Target Groups

Multibillion-dollar annual revenue opportunity as a global solution.

Opportunities kuva 1.png

Recurring revenue stream through probe covers and SaaS-solution

Opportunity Saas Lander.png

Largely unused technology with huge growth potential

Opportunity Orsinus Lander.png

No direct competitors in the current market

Opportunity Competitor Lander.png

Strong possibility to crossover to B2C market with remote heathcare

Opportunity House Lander.png

Investor Opportunities

bottom of page